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ABSTRACT
Introduction: There is an evidence gap about how to
best treat patients with prior coronary artery bypass
grafts (CABGs) presenting with non-ST segment
elevation acute coronary syndromes (NSTE-ACS)
because historically, these patients were excluded from
pivotal randomised trials. We aim to undertake a pilot
trial of routine non-invasive management versus
routine invasive management in patients with NSTE-
ACS with prior CABG and optimal medical therapy
during routine clinical care. Our trial is a proof-of-
concept study for feasibility, safety, potential efficacy
and health economic modelling. We hypothesise that a
routine invasive approach in patients with NSTE-ACS
with prior CABG is not superior to a non-invasive
approach with optimal medical therapy.
Methods and analysis: 60 patients will be enrolled
in a randomised clinical trial in 4 hospitals. A screening
log will be prospectively completed. Patients not
randomised due to lack of eligibility criteria and/or
patient or physician preference and who give consent
will be included in a registry. We will gather information
about screening, enrolment, eligibility, randomisation,
patient characteristics and adverse events (including
post-discharge). The primary efficacy outcome is the
composite of all-cause mortality, rehospitalisation for
refractory ischaemia/angina, myocardial infarction and
hospitalisation for heart failure. The primary safety
outcome is the composite of bleeding, stroke,
procedure-related myocardial infarction and worsening
renal function. Health status will be assessed using
EuroQol 5 Dimensions (EQ-5D) assessed at baseline
and 6 monthly intervals, for at least 18 months.
Trial registration number: NCT01895751
(ClinicalTrials.gov).
KEY QUESTIONS
What is already known about this subject?
▸ Patients with a prior coronary artery bypass graft
(CABG) were excluded from some of the key clinical
trials of routine invasive management versus conserva-
tive management. There is an evidence gap on the
safety and efficacy of invasive management in these
patients.
What does this study add?
▸ We will obtain ‘proof-of-concept’ information on feasi-
bility, safety and potential efficacy of a non-invasive
approach including optimal medical therapy compared
with a routine invasive approach in patients with an
acute non-ST segment elevation acute coronary syn-
drome (NSTE-ACS) with prior CABG, including health
outcomes beyond 1 year.
How might this impact on clinical practice?
▸ The results of our trial will provide preliminary infor-
mation on the rationale for routine non-invasive man-
agement in medically stable patients with prior CABG
and a NSTE-ACS. The results of this pilot trial will
inform the rationale for a substantive clinical trial that
would be designed and powered to assess the effects
of routine non-invasive versus routine invasive man-
agement on health and economic outcomes in this
patient group. If our hypothesis proves correct, then
routine non-invasive management could be initially
adopted for patients except the minority with recurrent
ischaemia. Results from a future substantive trial
would have the potential to be implemented in routine
clinical practice, with the potential to reduce variations
in clinical practice, enable more efficient resource util-
isation and allow patients with NSTE-ACS with prior
CABG to reach critical points in the care pathway more
quickly.
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INTRODUCTION
Occlusive disease of saphenous vein coronary artery
bypass grafts (CABGs) is a common occurrence within
10 years of surgery,1–3 meaning patients with prior
CABG have a progressive longer term risk of recurrent
ischaemia, including angina and myocardial infarction,
heart failure (HF) and death. Given the large number
of CABG survivors in the UK, and the complexities of
their health relating to increasing age and comorbidity,
this group of patients represents an increasing challenge
to healthcare providers globally.
In this article, we describe the clinical issues relating
to the management of patients with a non-ST segment
elevation acute coronary syndrome (NSTE-ACS). We
then discuss the rationale and study design of a rando-
mised controlled pilot trial of routine invasive manage-
ment versus conservative non-invasive, and a prospective
screening log and registry of patients who were not
randomised.
Epidemiology: CABG surgery is commonly performed
worldwide based on historical evidence of benefit over
medical therapy and recent evidence of prognostic benefits
over percutaneous coronary intervention (PCI).4 5
However, occlusive saphenous vein graft disease affects
approximately 1 in 10 patients within 12 months of
surgery,1 1 in 5 patients by 3 years3 and two-thirds of
patients by 10 years.1 2 Furthermore, disease in the native
coronary arteries may also progress and calcify.
Consequently, even though vein graft occlusion may initially
be subclinical, angina or myocardial infarction (MI) occurs
in most patients by 10 years after CABG surgery. Repeat
revascularisation (almost always by PCI) may be required in
approximately two-thirds of patients by 12 years,6 7 and inva-
sive procedures in patients with prior CABG may be asso-
ciated with a higher risk of complications acutely and
suboptimal outcomes in the longer term.6 7
Scale of the matter: Chest pain is the commonest reason
for hospital admission in the UK and more than 1 in
10–15 patients admitted to hospital with an acute
NSTE-ACS have a history of prior CABG.
(Lack of ) clinical evidence, controversy, rationale: Pivotal
clinical trials that compared routine invasive manage-
ment versus conservative non-invasive management in
unstable coronary syndromes, for example,
Thrombolysis In Myocardial Infarction IIIb (TIMI IIIb),8
Fast Revascularisation during InStability in Coronary
artery disease (FRISC II) Value of First Day
Angiography/Angioplasty In Evolving Non-ST Segment
Elevation Myocardial Infarction: An Open Multicenter
Randomised Trial (VINO)10 and Randomised
Intervention Treatment of Angina 3 (RITA 3),11
excluded patients with prior CABG (tables 1 and 2).
Clinical guidelines recommend a routine early invasive
strategy in higher risk patients with NSTE-ACS.12–14
However, invasive management is performed less often
in patients with NSTE-ACS with prior CABG, probably
because the balance of risks and benefits is less favour-
able in these patients compared with in NSTE-ACS
without prior CABG.15–17 Furthermore, when invasive
management is performed, PCI is less likely in patients
with prior CABG,16–18 implying a lower likelihood of
benefit with a routine invasive strategy. Real-world evi-
dence implies clinical practice departs from the results
of systematic reviews19 and the guidelines.20 Overall, evi-
dence is lacking to inform the validity of current guide-
line recommendations,12–14 and in our view, the safety
and effectiveness of a routine invasive approach in
patients with prior CABG and NSTE-ACS is called into
question.
Non-invasive diagnostic testing
CT coronary angiography is useful for imaging graft
patency; however, it has limited utility to resolve sten-
osis severity in chronic calcific coronary disease.
Routine stress testing in patients with recent
NSTE-ACS and known coronary disease is not
evidence-based. Stress tests are used variably in clinical
practice (or not at all), according to clinician prefer-
ence, patient eligibility and local availability. Stress
perfusion cardiac MRI (CMR) might be diagnostically
useful; however, it is impractical, since a routine strat-
egy based on CMR would be qualified because of lack
of availability (eg, stress CMR is not uniformly avail-
able across the National Health Service (NHS), espe-
cially for patients in an urgent care pathway), patient
ineligibility (eg, pacemaker) or non-compliance (eg,
claustrophobia, back pain).
Advances in interventional management
PCI continues to evolve through advances in technolo-
gies and technical skills. In recent years, specialist
Table 1 Clinical trials of invasive versus conservative
management in patients with NSTE-ACS*
Trials with
CABG patients
Year
published
Trials
without
CABG
patients
Year
published
VANQWISH22 1998 TIMI-IIIb8 1994
TRUCS23 2000 FRISC II9 1999
TACTICS-TIMI1810 24 2001 RITA-311 2002
ICTUS25 2005 VINO26 2002
CABG-ACS27 After May
2014
Italian Elderly ACS
Study40
2012
OASIS-5 women41 2012
*TACTICS is the only trial to have reported results with specific
reference to patients with NSTE-ACS with prior CABG.24
CABG-ACS, Coronary Artery Bypass Graft-Acute Coronary
Syndrome; ICTUS, Invasive versus Conservative Treatment in
Unstable Coronary Syndromes; NSTE-ACS, non-ST segment
elevation acute coronary syndromes; TRUCS, Treatment of
Refractory Unstable angina in geographically isolated areas
without Cardiac Surgery; VANQWISH, Veterans Affairs
Non–Q-wave Infarction Strategies In Hospital trial.
2 Lee MMY, Petrie MC, Rocchiccioli P, et al. Open Heart 2016;3:e000371. doi:10.1136/openhrt-2015-000371
Open Heart
group.bmj.com on May 12, 2016 - Published by http://openheart.bmj.com/Downloaded from 
techniques have developed with ‘antegrade’ and ‘retro-
grade’ approaches to recannalise chronic totally
occluded coronary arteries.21 The potential benefits of
new approaches for complex PCI in CABG patients
merit prospective evaluation in the future trial.
Overall hypothesis: Considering efficacy, safety and
health economics, a routine conservative (and selectively
invasive) approach in patients with NSTE-ACS with prior
CABG will be an acceptable alternative to the routine
invasive approach, which is the current standard of care.
Active efficacy hypothesis: Compared with a routine non-
invasive approach, a routine invasive approach in
patients with NSTE-ACS with prior CABG is associated
with a lower rate of all-cause mortality, recurrent MI or
HF.
Active safety hypothesis: Compared with a routine inva-
sive approach, a routine non-invasive approach in
patients with NSTE-ACS with prior CABG is associated
with a lower rate of adverse events related to safety
during the index hospitalisation.
Health economics hypothesis: Compared with a routine
invasive approach, a routine non-invasive approach is
cost-saving and associated with reduced resource
utilisation.
Pilot study objectives to inform a potential future clinical
trial: To obtain information on: (1) the absolute number
of patients admitted with an NSTE-ACS and a prior
history of CABG; (2) number of screen failures (and the
reasons); (3) enrolment rate; (4) randomisation rate;
(5) reasons for failure to obtain informed consent in
potentially eligible patients or failure to randomise (clin-
ical registry); (6) medical profile, including comorbidity;
(7) revascularisation rates with PCI or CABG; (8) dur-
ation of index admission; (9) serious adverse events,
including rehospitalisation (and the causes), and death
(and the causes), as adjudicated by a Clinical Event
Committee (CEC) blinded to treatment group assign-
ment. Some pivotal clinical trials excluded patients with
prior CABG, which we think qualifies the current guide-
lines that recommend invasive management in
NSTE-ACS and prior coronary disease (including prior
CABG).12 13
METHODS AND ANALYSIS/DESIGN
Overall aim: To undertake a pilot trial of routine con-
servative non-invasive management versus routine
invasive management in patients with NSTE-ACS with
prior CABG who are treated according to standard
care with optimal medical therapy (OMT) in NHS
hospitals (figure 1). The aim of the pilot is to assess
the rationale and provide a rehearsal for the main
trial.
Primary aims: (1) Compared with routine non-invasive
management, to assess if a routine invasive strategy is
more effective in symptomatic patients with prior CABG
compared with OMT; (2) compared with routine inva-
sive management, to assess if a routine non-invasive
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strategy is associated with fewer major complications and
hence is safer; (3) to prospectively quantify resource util-
isation in the NHS with each treatment strategy, derive
the difference in the quality-adjusted life years (QALYs)
and hence provide preliminary health economic
information.
Secondary aims: To evaluate: (1) the components of the
primary composite outcomes for efficacy and safety; (2)
quality of life (EuroQol 5 Dimensions (EQ-5D) at base-
line and six monthly intervals for a minimum of 18
months); (3) Canadian Cardiovascular Society (CCS)
angina class at baseline and six monthly intervals for a
minimum of 18 months; (4) repeat invasive manage-
ment during follow-up; (5) freedom from coronary
and/or bypass graft intervention; (6) secondary care
costs; (7) the nature and extent of multimorbidity
during the index hospitalisation; (8) the nature and
extent of native coronary artery and graft disease, includ-
ing culprit lesion characteristics; (9) a registry of the
patients who were not randomised, including the
reasons for not being randomised (physician-directed,
patient-directed or both) and their clinical character-
istics at enrolment and subsequent outcomes during
follow-up.
Accordingly, all invasive coronary interventional proce-
dures will be reported:
A. Elective;
B. Non-elective unplanned (as adjudicated by the
CEC).
Health economics: Quality of life, direct healthcare costs,
adverse events and their economic consequences over a
patient’s lifetime are key considerations to inform
whether or not a routine conservative approach would
be acceptable in patients with NSTE-ACS with prior
CABG.12 28–35 At this stage, we are uncertain of the
potential longer term economic value of routine conser-
vative management. A preliminary economic model will
be designed to provide an estimate of the lifetime incre-
mental costs, effects and net monetary benefit of a con-
servative treatment approach in patients with
CABG-ACS. The model will synthesise future data from
the pilot trial and the literature (eg, TACTICS CABG
analysis).24
Second, we are also uncertain on the optimal design
of the future trial, including whether health economic
results should be the primary objective. Value of informa-
tion analyses will illustrate where additional information
in a future trial will have the most value in increasing
Figure 1 Flow diagram of Coronary Artery Bypass Graft-Acute Coronary Syndrome (CABG-ACS) trial. Patients who provide
consent will enter either the (1) randomised trial or (2) registry (ie, based on the presence of exclusion criteria, or physician or
patient preference). Patients who do not provide consent and/or are ineligible will enter the (3) screen failure group. A change in
the treatment strategy (eg, from non-invasive to invasive management, or vice versa) within the first 30 days from randomisation
is a cross-over.
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confidence in net monetary benefit. Such information
will provide evidence for the optimal design of a future
trial, including considerations of, but not limited to:
whether it is needed, sample size, length of follow-up
and relevant economic outcomes.
Pilot: We aim to prospectively gather information on
the overall feasibility of conducting a clinical trial of
routine non-invasive versus routine invasive management
in recently hospitalised patients with an acute NSTE-ACS
and prior CABG. The aim of the pilot is to mimic the
main trial and assess whether or not random allocation
of these treatment strategies and compliance with the
protocol is feasible. Clinical research nurses will support
enrolment and follow-up assessments on two of the four
sites. NHS clinicians will support enrolment and
follow-up assessments on all of the sites. We specifically
aim to gather information on screening, recruitment,
randomisation (to medical therapy or invasive manage-
ment), cross-over rates and serious adverse events in
patients with prior CABG and a recent NSTE-ACS to
inform the feasibility and design of a future definitive
clinical trial. Researchers and nurses independent of the
clinical team will conduct follow-up for adverse events.
Consent: All randomised and registry patients will
provide written informed consent as soon as feasible
after hospital admission and prior to referral for coron-
ary angiography. Patients will be given an information
sheet prior, and may opt out at any time.
HOW THE SAMPLE WILL BE SELECTED: STUDY
POPULATION
Setting and feasibility: The pilot study will involve 60 ran-
domised patients recruited in two large urban hospitals
(Glasgow Western Infirmary and Glasgow Royal
Infirmary) and two regional district general hospitals
(Royal Alexandra Hospital, Paisley and Royal Blackburn
Hospital (RBH)). These hospitals were selected in order
to reflect the diversity of secondary care in the UK NHS
and different models of service provision. One of these
hospitals (RBH) has an onsite cardiac catheterisation
laboratory, whereas the other hospitals do not. In these
hospitals, patients are triaged for invasive management
by referral and transfer to the regional cardiothoracic
centre (Golden Jubilee National Hospital (GJNH)). The
GJNH and RBH provide invasive care for the West of
Scotland (2.5 million) and East Lancashire (0.5
million), respectively.
Screening: The clinical research team on each site will
screen for patients admitted during unscheduled emer-
gency care with a suspected acute NSTE-ACS and prior
CABG. Screening will take place in the acute medical
and cardiology wards during the course of routine
healthcare. Patients who are invited to participate
should be eligible for either treatment option. Each
patient will be given a corresponding site and study
number, and entered into a screening log. Patients who
do not provide consent will be included in the ‘screen
failure’ log. Only de-identified information will be con-
tained in the screening log including age, gender,
medical history, date of admission, date of discharge,
angiography (yes/no/date). The community health
index (CHI) or NHS number will be recorded to enable
electronic record linkage. Patients 18 years and older of
both sexes, with a history of NSTE-ACS and who are eli-
gible for either invasive management with coronary and
graft angiography or non-invasive management will be
invited to participate. Patients who fulfil the inclusion
criteria and who do not have exclusion criteria
(described in box 1) will be enrolled and randomised as
appropriate.
Randomisation: After informed consent, patients are
randomised with an interactive voice recognition system
from the trials unit, to one of two groups: initial medical
management or initial invasive management. All patients
will receive OMT with treatments prescribed at the dis-
cretion of the attending physician, and guidance on
uptitration of anti-ischaemic drugs is provided in an
investigator guideline. OMT includes dual antiplatelet,
antithrombotic and anti-ischaemic therapies as per local
protocols and international guidelines.12 13
Non-invasive group: According to the trial protocol,
study participants who have been randomised to the
non-invasive group may be referred for invasive manage-
ment if one of the following prespecified criteria are
met: (1) recurrent or refractory (class III or IV) angina
with documented ischaemic ECG changes while on
‘optimal’ anti-ischaemic therapy; (2) new ST-segment
elevation in two contiguous leads without Q waves or T
wave inversion greater than 3 mm or development of
haemodynamic instability; or (3) a deterioration in HF
status (consistent with Killip class 3 or 4) that the attend-
ing clinician judges to be ischaemia-related based on the
presence of symptoms, ECG changes and cardiac bio-
marker elevation.
Invasive group: Timed as appropriate according to local
hospital protocols. Usually, invasive management is per-
formed early (ie, ≤72 h wherever possible) from hospital
admission. Invasive management includes coronary and
Box 1 Eligibility criteria for participation in the rando-
mised trial
Inclusion criteria
▸ Unstable angina or non-ST segment elevation myocardial
infarction
▸ Stabilised symptoms without recurrent chest pain or intraven-
ous therapy for 12 h when ambulant
▸ Prior coronary artery bypass surgery
Exclusion criteria
▸ Refractory ischaemia (ie, recurrent angina with minimal exer-
tion or at rest (ie, Canadian Cardiovascular Society class III or
IV) not controlled by medical therapy)
▸ Cardiogenic shock
▸ Inability to give informed consent
▸ Unsuitable for invasive management
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graft angiography and coronary and/or graft revasculari-
sation with PCI and/or CABG, as clinically appropriate.
Registry: Information will be prospectively recorded in
a registry for patients with an acute NSTE-ACS and prior
CABG who are not randomised. The reasons for non-
participation in the randomised trial will be prospect-
ively recorded. The reasons may be the presence of
exclusion criteria, unsuitability for either invasive or
non-invasive management, physician preference, patient
preference, or a combination of these factors. The regis-
try information will provide insights to reflect an ‘all-
comers’ real-world population. The registry will also
inform on the feasibility of a future substantive rando-
mised trial. The baseline information and the follow-up
assessments are intended to be collected in the same
way for the registry and randomised trial participants.
Information (clinical characteristics, invasive and non-
invasive tests, health outcomes and quality of life during
follow-up) in the registry patients will be obtained in the
same way as the trial patients, that is, with case note
review, telephone contact or a hospital visit and during
the longer term by electronic record linkage.
Screen failure: For screened patients who are (1) eligible
but do not consent to participate in the randomised trial
or registry, or (2) ineligible, then the reason(s) for not
participating will be documented. No further clinical
information will be recorded.
Sample size calculation: The sample size in the
CABG-ACS pilot trial is n=60 patients. We chose this
number in order to gain reasonably representative infor-
mation on the characteristics of patients with NSTE-ACS
with prior CABG in contemporary practice to be
enrolled in different secondary care settings in order to
be representative of the diversity in UK hospitals. We
included four hospitals differing in geographic location,
availability of catheter laboratory facilities onsite (or
not), and hospital type (academic vs regional).
The sample size was selected to enable the feasibility
of randomisation, and the reasons for not being rando-
mised were to be prospectively assessed on multiple
occasions. As this pilot was an exploratory,
proof-of-concept trial, a sample size calculation was not
performed. The trial was designed but not powered to
assess for between-group differences in the rates of the
primary outcome.
Outcomes: Serious adverse events during the index
admission and follow-up will be evaluated from review of
patient records obtained during usual care, and elec-
tronic health databases, including the CHI number and
NHS number. The occurrence of all of these outcomes
will be prospectively entered into an electronic clinical
research form.
Clinical Event Committee
An independent CEC is proposed to review the primary
efficacy and safety end points. The CEC will review cases
of interest to determine if they meet the criteria defined
in this charter. Causality assessments will not be made by
the CEC, nor will the committee possess governance
authority. The CEC will be blinded where possible
regarding all information relating to the randomisation
group. The CEC will include four cardiovascular physi-
cians who have expertise in the diagnosis and treatment
of cardiovascular disorders and in the medical aspects of
clinical trials. The CEC will have a Chairman and coord-
inator to assist with preparation of de-identified source
clinical data, reports and communication with the Trials
Unit. The CEC will follow a predetermined adjudication
charter.
Primary outcome: The primary outcome is the postran-
domisation rate of major adverse events (co-primary
composite outcome), including one composite outcome
for efficacy and one composite outcome for safety. The
comparison between the incidences of each outcome
according to treatment group will assess the
between-group difference in the proportion of major
adverse events in patients allocated to non-invasive con-
servative management compared with invasive manage-
ment. The trial is designed to assess the feasibility of
recruiting and randomising such a population but is not
powered to detect a between-group difference in clinical
outcomes.
Primary efficacy outcome: Defined as all-cause mortality,
rehospitalisation for refractory ischaemia/angina, MI or
hospitalisation for HF. The end points will be assessed
during the study until the final randomised patient has
completed 18 months follow-up.
Primary safety outcome: Defined as bleeding (Bleeding
Academic Research Consortium (BARC) types 2–4),36
stroke, procedure-related MI (type 4a, universal defin-
ition), worsening renal function or haemodialysis during
the index hospitalisation.
Definitions of adverse events
Death: All-cause, sudden cardiac death, death due to MI,
death due to HF, death due to stroke, death due to
extra-axial haemorrhage, death due to cardiovascular
operation, death due to other cardiovascular cause (eg,
infective endocarditis), presumed cardiovascular death
(undetermined cause of death), non-cardiovascular
death.37 38
Procedure-related MI: According to the universal defin-
ition of MI. A postprocedure ECG will enable diagnosis
of Q versus non-Q MI.
Stroke is defined as the presence of a new focal neuro-
logical deficit thought to be vascular in origin, with signs
or symptoms lasting more than 24 h; subdural
haemorrhage.
Major bleeding is defined according to the BARC
criteria.36
Worsening renal function is defined as deterioration in
estimated glomerular filtration rate ≥25% of baseline
during the index admission.
Follow-up and timing of outcome evaluations: Follow-up
(via telephone contact, clinic visits, letter) with comple-
tion of quality of life assessments (EQ-5D) will be
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maintained at six monthly intervals until a minimum of
18 months follow-up has been reached for the final
recruited patient. Data will be held for up to 20 years to
enable long-term follow-up analyses.
Following randomisation, clinical assessments will
involve gathering information from the standard-of-care
clinical reviews (end of hospitalisation, 30–42 days and
1 year) and also from clinical contacts recorded in the
patients’ medical records. In West of Scotland hospitals,
a single system of electronic patient records is used for
all hospital attendances and correspondence with
primary care.
Cross-over: A cross-over between groups is defined as a
change of treatment strategy from invasive to non-
invasive management, or vice versa. In addition, we pre-
defined cross-over as occurring within 30 days after
randomisation.
Secondary outcomes
1. Quality of life (EQ-5D assessed at baseline and six
monthly intervals for a minimum of 18 months);
2. CCS angina class;
3. Hospitalisation for refractory ischaemia and/or
angina: refractory ischaemia/refractory angina,
defined as recurrent ischaemic symptoms lasting
more than 5 min, while on OMT (at least two antian-
ginal treatments) with documented characteristic
ECG changes indicative of ischaemia and requiring
an additional intervention. An additional interven-
tion is defined as reperfusion therapy for MI, cardiac
catheterisation and insertion of intra-aortic balloon
pump or revascularisation procedure (PCI or CABG
surgery) within 48 h of the onset of this episode. This
definition is in line with the Timing of Intervention
in Acute Coronary Syndromes (TIMACS) trial;37
4. Repeat invasive management during follow-up;
5. Freedom from coronary and/or bypass graft
intervention;
6. Health economics: secondary care costs and
procedure-related costs (diagnostic tests, PCI,
CABG), hospital bed days including intensive care,
high dependency unit, general medical.
Health economics
1. Estimate the cost-effectiveness of routine invasive
approach versus conservative management for
patients with NSTE-ACS with prior CABG;
2. Identify where additional information in a future trial
will have the most value in increasing confidence in
net monetary benefit to the NHS.
Secondary care and procedure-related costs (diagnostic
tests, PCI, CABG), hospital bed days (including intensive
care, high dependency unit, general medical) will be
recorded prospectively for index and subsequent hospi-
talisations. This information will be used to provide pre-
liminary information on health economics.
Early estimates of cost-effectiveness may exhibit a large
degree of decision uncertainty. Designing a definitive
trial to assess the relative clinical and economic out-
comes is challenging given the paucity of evidence.
Important considerations to consider are: whether it is
needed, sample size, length of follow-up and relevant
economic outcomes. Preliminary economic modelling
and value of information methods can help identify
where additional information in a future trial will have
the most value.32–34 The following section describes the
methods to be used in the economic evaluation. The
proposed plan follows guidance published by the
National Institute for Health and Care Excellence
(NICE).39
The economic evaluation will be a cost-utility analysis
will full incremental analysis.
Perspective, time horizon, discount rate
The analysis will be conducted from the perspective of
the NHS and Personal Social Services (PSS). Differences
in major adverse cardiac events may result in lifetime dif-
ferences in cost and health effects. Thus, the analysis
will use a lifetime time horizon. A 3.5% discount rate
will be used for both health and cost effects.
Value of information methods used to identify which
outcomes affect the probability of cost-effectiveness and
likelihood of NHS adoption under commonly used deci-
sion thresholds (£20 000–£30 000/QALY).32–35 Value of
information analyses will also be used to estimate the
optimal sample size of a future definitive trial.
Statistics: The Robertson Centre for Biostatistics will act
as an independent coordinating centre for data manage-
ment and conduct statistical analyses. The Centre is
registered with a Clinical Trials Unit (National Institute
for Health Research (NIHR) Registration number: 16).
Summary statistics will be performed with data from the
pilot study and registry. The proportions of patients with
adverse events will be assessed with a χ2 test. Summary
analyses will be performed on the screening log data.
Statistical analysis plan
Baseline data
Baseline characteristics of the randomised participants
(split by randomised group) and for the registry partici-
pants will be summarised using mean (SD for continu-
ous measurement), or median (lower quartile, upper
quartile for skewed data) and count per cent for categor-
ical variables. Baseline characteristics for randomised
participants and registry participants will be compared
using t tests, Mann-Whitney tests and χ2 tests (or Fisher’s
exact tests) as appropriate.
Longer term clinical outcomes
Numbers of events and numbers (%) of patients with
events will be summarised. Time to first event of each
type will be analysed using Cox proportional hazards
regression models, with estimated hazard ratios, 95% CIs
and p values using the Wald statistic. Time to event
curves will be created using the Kaplan-Meier method.
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Shorter term safety outcomes
Numbers of events and numbers (%) of patients with
events will be summarised. Relative frequency of event
types will be compared using Fisher’s exact tests and
ORs and 95% CIs for treatment effects estimated using
exact logistic regression.
Changes in quality of life over time will be analysed at
each time point using analysis of covariance adjusting
for baseline and using repeated measures analysis of
postintervention data adjusting for baseline. The prespe-
cified health outcomes will be analysed at each time
point using ordinal logistic regression adjusted for
baseline.
All serious adverse events will be summarised accord-
ing to system organ class and preferred term.
ETHICS AND DISSEMINATION
The research study was reviewed and approved by the
National Research Ethics Service (Reference
11-WS-0116).
Potential benefits to participants include avoidance of
harmful invasive management and avoidance of longer
term stent failure. No additional interventions are pro-
posed nor are procedures withdrawn that would be
needed on clinical grounds. While the intention-to-treat
in each group is either with non-invasive or invasive
management, all treatment options remain available
according to patient and physician preference, that is,
patients initially randomised to medical therapy may
undergo invasive management and vice versa.
Data management and biostatistics: For confidentiality,
patients shall be assigned an identification code at the
time of recruitment.
Trial management
A trial management group including the researchers and
Local Principal Investigator on each of the four sites
coordinated the study’s activities on a day-to-day basis.
The NHS Sponsor monitored the trial. Since the trial
was a pilot, there was no Independent Data and Safety
Monitoring Committee (IDMC).
The trial is publically registered:27 http://clinicaltrials.
gov/ct2/show/NCT01895751.
Expected value of results: Since clinical trials usually
excluded patients with prior CABG, clinical guidelines
are not evidence-based with respect to this group of
patients meaning that clinicians lack knowledge, and a
clinical decision in favour of invasive management (as
per guidelines) is not well informed. Our project
addresses this lack of evidence. If a future substantive
trial confirms our overall hypothesis, then routine non-
invasive management should be adopted generally,
except for the minority with refractory angina who
would be selectively referred for invasive angiography.
The trial results will help reduce unnecessary and
expensive diagnostic investigations (ie, stress tests) and
provide clarity for decision-making. The results from a
future definitive trial could be rapidly implemented in
routine NHS practice. This research proposal will
provide essential information to inform the design of
the future substantive trial, including whether or not it
should be performed and if so, its sample size and
primary and secondary outcomes.
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